Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Pollard

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
British Journal of Cancer|May 27, 2021
Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumoursGeoffrey I Shapiro, Robert Wesolowski, Craig Devoe, et al.
British Journal of Cancer|May 27, 2021
Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumoursMark R Middleton, Emma Dean, Thomas R J Evans, et al.
Disease Models & Mechanisms|October 13, 2023
A Drosophila model targets Eiger/TNFα to alleviate obesity-related insulin resistance and macrophage infiltrationZhasmine Mirzoyan, Alice Valenza, Sheri Zola, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 10, 2007
(S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1beta and IL-18Woods Wannamaker, Robert Davies, Mark Namchuk, et al.
Biorxiv : the Preprint Server for Biology|July 18, 2023
A Novel Drosophila Model to Investigate Adipose Tissue Macrophage Infiltration (ATM) and Obesity highlights the Therapeutic Potential of Attenuating Eiger/TNFα Signaling to Ameliorate Insulin Resistance and ATMZhasmine Mirzoyan, Alice Valenza, Sheri Zola, et al.
British Journal of Haematology|September 16, 2009
In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465Joseph M Negri, Douglas W McMillin, Jake Delmore, et al.
Nature Communications|June 11, 2022
Mechanism of glycogen synthase inactivation and interaction with glycogeninLaura Marr, Dipsikha Biswas, Leonard A Daly, et al.
Journal of Medicinal Chemistry|May 11, 2019
Rational Design of 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine (VX-970, M6620): Optimization of Intra- and Intermolecular Polar Interactions of a New Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase InhibitorRonald Knegtel, Jean-Damien Charrier, Steven Durrant, et al.
BMJ Open|February 2, 2022
Investigating the day-to-day impact of hypoglycaemia in adults with type 1 or type 2 diabetes: design and validation protocol of the Hypo-METRICS applicationUffe Søholm, Melanie Broadley, Natalie Zaremba, et al.
Hepatology (Baltimore, Md.)|August 14, 2009
Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitisRafal P Witek, W Carl Stone, F Gamze Karaca, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
British Journal of Cancer|May 27, 2021
Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumoursGeoffrey I Shapiro, Robert Wesolowski, Craig Devoe, et al.
British Journal of Cancer|May 27, 2021
Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumoursMark R Middleton, Emma Dean, Thomas R J Evans, et al.
Disease Models & Mechanisms|October 13, 2023
A Drosophila model targets Eiger/TNFα to alleviate obesity-related insulin resistance and macrophage infiltrationZhasmine Mirzoyan, Alice Valenza, Sheri Zola, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 10, 2007
(S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1beta and IL-18Woods Wannamaker, Robert Davies, Mark Namchuk, et al.
Biorxiv : the Preprint Server for Biology|July 18, 2023
A Novel Drosophila Model to Investigate Adipose Tissue Macrophage Infiltration (ATM) and Obesity highlights the Therapeutic Potential of Attenuating Eiger/TNFα Signaling to Ameliorate Insulin Resistance and ATMZhasmine Mirzoyan, Alice Valenza, Sheri Zola, et al.
British Journal of Haematology|September 16, 2009
In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465Joseph M Negri, Douglas W McMillin, Jake Delmore, et al.
Nature Communications|June 11, 2022
Mechanism of glycogen synthase inactivation and interaction with glycogeninLaura Marr, Dipsikha Biswas, Leonard A Daly, et al.
Journal of Medicinal Chemistry|May 11, 2019
Rational Design of 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine (VX-970, M6620): Optimization of Intra- and Intermolecular Polar Interactions of a New Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase InhibitorRonald Knegtel, Jean-Damien Charrier, Steven Durrant, et al.
BMJ Open|February 2, 2022
Investigating the day-to-day impact of hypoglycaemia in adults with type 1 or type 2 diabetes: design and validation protocol of the Hypo-METRICS applicationUffe Søholm, Melanie Broadley, Natalie Zaremba, et al.
Hepatology (Baltimore, Md.)|August 14, 2009
Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitisRafal P Witek, W Carl Stone, F Gamze Karaca, et al.
Pageof 5